Literature DB >> 9276525

Hyperinducible expression of the interferon-gamma (IFN-gamma) gene and its suppression in systemic lupus erythematosus (SLE).

L Gerez1, T Shkolnik, O Hirschmann, M Lorber, G Arad, R Kaempfer.   

Abstract

Transient expression of IFN-gamma and IL-2 mRNA and its control by post-transcriptional and suppressive mechanisms were analysed in phytohaemagglutinin-induced peripheral blood mononuclear cells (PBMC) from 47 patients with SLE and 31 age-matched normal donors, using quantitative hybridization with antisense RNA probes. In SLE, basal levels of gene expression did not deviate from those of normal donors, but strongly aberrant patterns were obtained upon induction. The ratio of subjects exhibiting highly inducible IFN-gamma gene expression in their PBMC to those showing moderate or low inducibility was increased five-fold in SLE (P = 0.003). High inducibility was observed for 43% of SLE patients and was equally pronounced in partial remission, mild or active disease. Inducibility of IL-2 mRNA, by contrast, remained similar to that for normal donors. However, regulation of IFN-gamma gene expression differed for mild SLE. Patients with mild disease showing high inducibility of IFN-gamma mRNA in their PBMC not only had the highest frequency of responders, but also the highest extent of an individual response, defined by superinduction of mRNA, to agents that relieve suppression (gamma-irradiation) or post-transcriptional down-regulation (cycloheximide). By contrast, patients with active SLE showing high IFN-gamma mRNA inducibility had normal suppressive capacity as well as post-transcriptional control. Hence, both high inducibility of the IFN-gamma gene and its suppression are relevant to disease. Hyperactivation of the IFN-gamma gene may be alleviated in mild SLE by a vigorous, concomitant activation of post-transcriptional control and of cell-mediated suppression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276525      PMCID: PMC1904755          DOI: 10.1046/j.1365-2249.1997.4471345.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  7 in total

Review 1.  RNA sensors: novel regulators of gene expression.

Authors:  Raymond Kaempfer
Journal:  EMBO Rep       Date:  2003-11       Impact factor: 8.807

2.  Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus.

Authors:  Lijun Song; Feng Qiu; Yuchen Fan; Feng Ding; Huaxiang Liu; Qiang Shu; Weiwei Liu; Xingfu Li
Journal:  J Clin Immunol       Date:  2012-09-09       Impact factor: 8.317

3.  Dynamic refolding of IFN-gamma mRNA enables it to function as PKR activator and translation template.

Authors:  Smadar Cohen-Chalamish; Anat Hasson; Dahlia Weinberg; Lise Sarah Namer; Yona Banai; Farhat Osman; Raymond Kaempfer
Journal:  Nat Chem Biol       Date:  2009-10-04       Impact factor: 15.040

4.  The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity.

Authors:  A N Theofilopoulos; S Koundouris; D H Kono; B R Lawson
Journal:  Arthritis Res       Date:  2001-02-14

5.  Core Fucosylation of the T Cell Receptor Is Required for T Cell Activation.

Authors:  Wei Liang; Shanshan Mao; Shijie Sun; Ming Li; Zhi Li; Rui Yu; Tonghui Ma; Jianguo Gu; Jianing Zhang; Naoyuki Taniguchi; Wenzhe Li
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

6.  Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus.

Authors:  Michelle D Catalina; Prathyusha Bachali; Nicholas S Geraci; Amrie C Grammer; Peter E Lipsky
Journal:  Commun Biol       Date:  2019-04-23

7.  Dysregulation of miR-155-5p and miR-200-3p and the Anti-Non-Bilayer Phospholipid Arrangement Antibodies Favor the Development of Lupus in Three Novel Murine Lupus Models.

Authors:  Luz Ángela Zárate-Neira; Sandra Sánchez-Barbosa; Abraham Pedroza-Torres; Albany Reséndiz-Mora; Carlos Wong; Isabel Baeza; Carlos Pérez-Plasencia; Carlos Wong-Baeza
Journal:  J Immunol Res       Date:  2017-12-04       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.